Metoprolol Succinate and Ramipiril Tablet
Description
MIPROOT METO 2.5
Metoprolol Succinate Extended Release 50 mg and Ramipril 2.5 mg Tablets
Division: DIABGLYM
Composition
Each extended-release tablet contains:
Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 50 mg
Ramipril IP — 2.5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Extended-release oral tablet
Product Description
MIPROOT METO 2.5 is a scientifically balanced antihypertensive and cardioprotective combination of Metoprolol Succinate Extended Release 50 mg and Ramipril 2.5 mg, formulated for the effective management of hypertension, coronary artery disease, heart failure, and long-term cardiovascular risk reduction. This combination provides dual cardiovascular protection by combining the sustained beta-1 selective blocking action of Metoprolol Succinate with the renin-angiotensin system inhibition of Ramipril, resulting in effective blood pressure control, reduced cardiac workload, and enhanced cardiovascular and renal protection.
Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, and protects cardiovascular and renal function.
MIPROOT METO 2.5 is particularly beneficial in patients with hypertension associated with coronary artery disease, post-myocardial infarction status, heart failure, diabetes, chronic kidney disease, left ventricular dysfunction, elderly hypertension, and patients requiring lower-dose ACE inhibitor therapy with long-term cardioprotective benefits.
Technical Knowledge of Metoprolol Succinate Extended Release and Ramipril
Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, cardiac output, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day.
Ramipril is converted to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing aldosterone secretion, promoting vasodilation, improving endothelial function, and preventing adverse cardiovascular remodeling.
The combination of Metoprolol Succinate Extended Release and Ramipril provides complementary cardiovascular mechanisms with enhanced antihypertensive, cardioprotective, and nephroprotective benefits.
Mechanism of Action
Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade.
Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, and protects cardiovascular and renal tissues.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual cardioprotective mechanism
Provides sustained 24-hour cardiovascular control
Reduces heart rate and myocardial workload
Supports cardiovascular and renal protection
Improves endothelial function
Helps prevent adverse cardiac remodeling
Suitable for long-term hypertension and cardiovascular management under medical supervision
Clinical Applications
MIPROOT METO 2.5 is commonly prescribed for essential hypertension, hypertension with coronary artery disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, post-myocardial infarction management, chronic heart failure, left ventricular dysfunction, elderly hypertension, and long-term cardiovascular risk reduction.
Facts About Metoprolol Succinate Extended Release and Ramipril
Metoprolol Succinate Extended Release is a long-acting beta-blocker with proven benefits in hypertension, ischemic heart disease, and heart failure. Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. The combination provides comprehensive blood pressure control, heart rate reduction, prevention of cardiovascular remodeling, and long-term organ protection. The Ramipril 2.5 mg strength is particularly useful for initiation of combination therapy and individualized dose titration.
Key Facts
Beta-blocker and ACE inhibitor combination therapy
Metoprolol Succinate Extended Release 50 mg for sustained heart rate control
Ramipril 2.5 mg for cardiovascular and renal protection
Provides 24-hour antihypertensive and cardioprotective action
Effective in hypertension, coronary artery disease, and heart failure
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
MIPROOT METO 2.5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, heart failure, and chronic kidney disease creates strong prescription demand and long-term market potential for this combination.
Why Choose MIPROOT METO 2.5 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate Extended Release 50 mg and Ramipril 2.5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented extended-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
MIPROOT METO 2.5 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Metoprolol Succinate Extended Release and Ramipril formulation.
